Keppra 1000mg Tablet contains Levetiracetam, an anticonvulsant agent used primarily for the treatment of epilepsy. It is indicated as adjunctive therapy for partial onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients aged four years and older. Levetiracetam’s mechanism of action is not fully understood, but it is believed to modulate synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, which may inhibit burst firing and reduce seizure activity. Keppra is administered orally, with dosing individualized based on patient age, renal function, and clinical response. The 1000mg strength is typically used in adults and adolescents, often divided into two doses per day to maintain therapeutic plasma concentrations. Common adverse effects include somnolence, dizziness, headache, and fatigue, though it is generally well tolerated. Caution is advised in patients with renal impairment, and dose adjustments may be necessary. Keppra has a low potential for drug interactions, making it a favorable option in polytherapy regimens. Patients should be monitored regularly for changes in seizure frequency, mood alterations, and any signs of hypersensitivity or behavioral disturbances. This medication should be used under strict medical supervision.